The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a nation-wide, longitudinal study, aimed at increasing the pace of investigation and discovery of treatments that slow or stop the progression of Alzheimer’s disease. The purpose of this study is to determine the relationships among clinical, imaging, genetic, and biomarker characteristics of the entire spectrum of Alzheimer’s disease from normal aging to dementia. For more than a decade, ADNI researchers have been working to better understand the disease. Now, in this next step, this initiative is studying how quickly brain cognition and function changes and how best to measure these changes.
ADNI3 is an observational study and no medications are involved. We are looking for participants with normal cognition, Mild Cognitive Impairment (MCI), or mild Alzheimer’s dementia. Participants may be fluent in English or Spanish. Participants will come in for yearly visits, which may be split up into multiple appointments. Over the course of the 5-year study, participants will undergo clinical, cognitive, and genetic tests, as well as MRI scans, PET scans, and at least one lumbar puncture. Participants are also asked to come in with a “study partner,” who may be a family member or close friend to aid in the study activities. If you are between 55-90 years old, in stable health, and are willing to undergo the procedures listed above, please contact the study coordinator at (212) 241-8329. Principal Investigator: Hillel Grossman, MD; GCO #91-208 (29) HS#17-01326, ISMMS IRB approved through 4/25/2023.